# Viral Vector Core

> **NIH NIH P50** · UNIVERSITY OF WASHINGTON · 2020 · $237,150

## Abstract

VIRAL VECTOR CORE: Summary/Abstract
This Viral Vector Core has been in operation for nearly 12 years, and its main role has been to support
the Wellstone Center in Seattle as a Scientific Research Resource Core. The Core also offers support to
non-Center members on a recharge basis. The Core provides high quality preparations of viral and
plasmid vectors to facilitate research related to the muscular dystrophies. Services offered by the Core
include providing consulting, reagents and training related to vector production. This includes production
of adeno-associated and lentiviral vectors and muscular dystrophy related reagents (cell lines, vector
backbones, protocols, antibodies etc) for members of this Center as well as laboratories in the US and
across the World to support their efforts related to gene therapy for the muscular dystrophies. The
Principle Investigator of the Vector Core is now Dr. Joel Chamberlain, who has worked closely with
Core personnel on AAV and retroviral vectors for more than 10 years. The manager of the Core is Dr.
James Allen. Dr. Allen, in conjunction with the Chamberlain, Russel, Odom and Hauschka labs has
established protocols for the production of adeno-associated viral vectors, particularly AAV6 and 9, but
also several other pseudotyped vectors including AAV1, 5, 7,8 and 8i, and VSVG-lentiviral vectors. For
many years such vectors and associated reagents have been supplied by us to laboratories around the
world as part of collaborations, and for the past 3.5 years (and a previous 5 year period) these reagents
have been provided via the Wellstone Center Vector Core lab. We also have numerous dystrophin and
utrophin cDNAs and antibodies that will be made available via this Core lab, as well as DM1, DUX4 and
associated RNAi vectors. We will provide high quality, high titer preparations of adeno-associated viral
(AAV) vectors based primarily on AAV serotypes 6 & 9, but also for AAV 1, 2, 8 and emerging new
and modified serotypes. These recombinant AAV (rAAV) vectors will be provided to members of the
Wellstone Center using funds from this Core, and to other muscular dystrophy researchers on a
recharge basis to cover costs. We also have numerous muscle disease related cDNAs and antibodies
that will be made available via this Core lab for all members of our Center. Training will allow investigators
to apply methods for production and purification of viral vectors (AAV and lentiviral) in their own labs as
desired, and will be advertised via the Center Web site. Consulting will be available to guide the use of the
AAV and lentiviral vectors. Finally, we will provide reagents (such as vector backbones, plasmids,
antibodies and protocols) that have been developed by members of this Wellstone Center to outside
labs.

## Key facts

- **NIH application ID:** 10008980
- **Project number:** 5P50AR065139-07
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** JOEL R CHAMBERLAIN
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $237,150
- **Award type:** 5
- **Project period:** 2014-05-07 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10008980

## Citation

> US National Institutes of Health, RePORTER application 10008980, Viral Vector Core (5P50AR065139-07). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10008980. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*